 we report on our first quarter 2023 financial results and discuss our plans for the future. 
 we also discuss the status of our ongoing clinical studies including the recently reported positive top line results from the first ever randomized placebo-controlled trial for nicotine e-cigarette cessation, the ORCA-3 trial. 
 we also discuss our plans for commercialization of cytisinicline and the potential for a new drug application for cytisinicline in the future.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 